File(s) not publicly available
Reason: data available at other sources
Metadata record for the manuscript: Multi-omics analysis of serial samples from metastatic TNBC patients on PARP inhibitor monotherapy provide insight into rational therapy combinations
This metadata record provides details of the data supporting the claims of the related manuscript: “Multi-omics analysis of serial samples from metastatic TNBC patients on PARP inhibitor monotherapy provide insight into rational therapy combinations”.
The related study evaluated the feasibility of real-time deep analysis of serial tumour samples from triple negative breast cancer patients to identify mechanisms of resistance and treatment opportunities as they emerge under therapeutic stress engendered by poly-ADP-ribose polymerase (PARP) inhibitors (PARPi).
Type of data: real-time deep analysis of serial tumor samples from triple negative breast cancer patients
Subject of data: Homo sapiens
Sample size: 3
Population characteristics: Eligibility criteria included biopsy proven metastatic triple negative breast cancer, ECOG PS ≤2, received ≤2 chemotherapeutic agents in the metastatic setting. Patients with prior PARP inhibtior or immune checkpoint blockade exposure in the metastatic setting were excluded.
Recruitment: Patients for this study were enrolled at Oregon Health and Science University Center for Health and Healing and Community Hematology and Oncology clinics.
Trial registration number: https://clinicaltrials.gov/ct2/show/NCT03544125
The raw DNA sequencing data generated during the current study, are available in the European Nucleotide Archive (ENA) at the following accession: https://identifiers.org/ena.embl:EGAS00001005479. As these files are controlled access, researchers must request access to the ENA data. The repository also includes clinical and phenotypic metadata and molecular data (including protein expression). The reverse phase protein array data (protein expression data), are also available via ENA.
HER2 immunohistochemistry data, Intracellular Signaling Protein Panel assay data, and data from the GeneTrails Solid Tumor Panel assay, are not publicly available, but will be made available on reasonable request. Please contact the Knight Diagnostic Laboratories at Oregon Health and Science University (OHSU), email: KDLClientServices@ohsu.edu, for more information on these datasets.
Corresponding author(s) for this study
Zahi I. Mitri, MD, MS; Oregon Health & Science University, 3181 SW Sam Jackson Park Rd. Mail Code: OC14HO, Portland, OR 97239. E-mail: firstname.lastname@example.org.
Marilyne Labrie, PhD; Oregon Health & Science University, 2720 S Moody Avenue: Mailcode: KR-PM, Portland, OR 97201. E-mail: email@example.com.
OHSU Institutional Review Board